Instructions for Rosuvastatin pills
Application instructions
Description
Pills coated with a film shell in white or almost white. Round, double-convex.
Active substances
Rozuvastatin
Release form
Tablets
Composition Rosuvastatin
Per 1 tablet: Active substance: calcium rosuvastatin - 41.660 mg, in terms of rosuvastatin - 40.0 mg. Auxiliary substances: lactose monohydrate (milk sugar) - 264,658 mg, microcrystalline cellulose - 46,314 mg, sodium croskarmellose - 17,684 mg, povidon-K25 9,924 mg, silica colloid - 3,880 mg, magnesium stearate - 3,880 mg. The envelope consists of hypromellose 6,600 mg, macrogol 4,000 - 1,800 mg, titanium dioxide 3,600 mg.
Testimony Rosuvastatin
- - Primary hypercholesterolemia (Fredrikson type IIa including familial heterozygous hypercholesterolemia) or mixed
- hypercholesterolemia (type IIb) as a supplement to diet when diet and other non-pharmacological treatments (e.g.,
- exercise reducing body weight) are inadequate.
- - Familial homozygous hypercholesterolaemia as a supplement to diet and
- other lipidising therapy (e.g. LDL-apheresis) or when such therapy is not effective enough.
- - Hypertriglyceridemia (type IV
- Fredrikson) as a supplement to the diet.
- - To slow the progression of atherosclerosis as a supplement to diet, patients are
- shown therapy to reduce the concentration of total HS and HS-LDL.
- - Primary prevention of major cardiovascular
- complications (stroke of arterial revascularization) in adult patients without clinical signs of coronary heart disease (IBS)
- but with an increased risk of its development (age over 50 years for men and over 60 years for women increased
- concentration of C-reactive protein (≥ 2 mg/l) with at least one additional risk factor such as arterial hypertension low
- concentration of HC-HDL smoking early onset family anamnesis IBS).
- Nosology (ICD codes)
- E78.0
- Pure hypercholesterolemia
- E78.1
- Pure hyperglyceridemia
- E78.2
- Mixed hyperlipidemia
- I21
- Acute myocardial infarction
- I63
- Brain infarction
- I70
- Atherosclerosis
Method of use and doses Rosuvastatin
Do not chew or break in swallowing whole water. The drug can be prescribed at any time of the day regardless of the time of ingestion. Before starting therapy with Rozuvastatin, the patient must follow a standard hypocholesterolemic diet and continue to follow it during treatment. The dose of the drug should be selected individually according to the objectives of the therapy and the therapeutic response to the treatment, taking into account the current recommendations on the target concentration of lipids. The recommended initial dose for patients starting to take the drug or for patients transferred from other GMG-CoA reductase inhibitors should be 5 or 10 mg of Rozuvastatin 1 time per day. When choosing the initial dose, the individual concentration of cholesterol should be taken into account and the possible risk of cardiovascular complications should be taken into account, and the potential risk of side effects should be assessed. If necessary, the dose can be increased to a greater extent after 4 weeks. Due to the possible side effects of taking a dose of 40 mg compared to lower doses of the drug, an increase of up to 40 mg after an additional dose above the recommended initial dose may only be taken in patients with severe hypercholesterolemia and high risk of cardiovascular complications (especially in patients with familial hypercholesterolemia) who have not achieved the desired result of the therapy at a dose of 20 mg and who will be under the supervision of a specialist.
